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Abstract
Background and methods. Host may have a role in the evolution of chronic HCV liver disease. We performed two cross-sectional
prospective studies to evaluate the prevalence of cirrhosis in first degree relatives of patients with cirrhosis and the role of two major
histocompatibility complex class III alleles BF and C4 versus HCV as risk factors for familial clustering.
Findings. Ninety-three (18.6%) of 500 patients with cirrhosis had at least one cirrhotic first degree relative as compared to 13 (2.6%)
of 500 controls, (OR 7.38; CI 4.21–12.9). C4BQ0 was significantly more frequent in the 93 cirrhotic patients than in 93 cirrhotic controls
without familiarity (Hardy–Weinberg equilibrium: 2 5.76, P = 0.016) and in 20 families with versus 20 without aggregation of HCV related
cirrhosis (29.2% versus 11.3%, P = 0.001); the association C4BQ0-HCV was found almost only in cirrhotic patients with a family history
of liver cirrhosis.
Conclusions. Our studies support the value of C4BQ0 as a risk indicator of familial HCV related cirrhosis.
© 2004 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
There is little data on the familial clustering of cirrhosis
and on its relationship with the known etiological factors of
the disease.
In a large multicenter case-control study about the risk
factors of cirrhosis [1], familiarity of chronic liver disease
was found to be significantly more frequent in cirrhotic
patients than in controls (141/1058 versus 62/1408; OR
3.02, CI 2.4–4.3, data not published). In a prospective
study of the natural history of cirrhosis in progress at our
unit, 73 out of 494 consecutive patients with cirrhosis
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(15%) had at least one first degree relative with cirrhosis
[2].
There is evidence that host genetic factors play a ma-
jor role in determining the outcome of HCV infection. I
and II class major histocompatibility complex (MHC) alle-
les are involved in the clearance of HCV infection and its
long term outcome [3–8]. The role of class III MHC al-
leles is well established in autoimmune hepatitis and pri-
mary biliary cirrhosis [9] but there is little data on how
they affect the clinical course of HCV infection [10]. We
report here two prospective studies. The first, assessing the
prevalence of cirrhosis among first degree relatives of cir-
rhotic patients and the prevalence of class III MHC C4
and BF alleles among patients with familial cirrhosis; the
second, investigating the relationship between C4B allele
deficit and HCV infection as a risk indicator for familial
aggregation.
1590-8658/$30 © 2004 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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2. Methods
2.1. First study: familiarity of cirrhosis
2.1.1. Patient recruitment
Between January 1994 and December 1997, 500 unrelated
patients with virus and/or alcohol related cirrhosis and 500
unrelated hospital controls with chronic non-hepatic disease,
pair matched for sex, age (±5 years) and time of admis-
sion (±6 months), were enrolled at “V. Cervello” Hospital
in Palermo. The study was approved by the local ethics com-
mittee and all the patients gave their consent to participate.
Patients with metabolic causes of cirrhosis were excluded.
The diagnosis of cirrhosis was biopsy-proven in 215 patients
and based on the presence of ascites and/or oesophageal
varices on endoscopy and/or signs of portal hypertension on
ultrasound and compatible biochemistry and physical signs
in the remaining 285 patients. Child–Pugh classification was
as follows: 295 (59%) A, 170 (34%) B and 35 (7%) C. All
cirrhotic patients with a diagnosis of hepatocellular carci-
noma were excluded. Relevant clinical data and a complete
family pedigree including number, age and sex of first de-
gree relatives were recorded on predefined standard forms.
Requested information on first degree relatives included (a)
survival status and, if deceased, age at death; (b) age and
sex of parents, siblings and children; (c) whether a diagno-
sis of liver cirrhosis had been made in family members. For
diagnostic verification secondary cases were traced first by
searching in our extensive files of patients admitted before
and during the study and in secondary cases not found in
our file, the diagnosis of cirrhosis was accepted only when
supported by medical records or discharge letters from other
hospitals, or by death certificates.
2.1.2. Cirrhosis in relatives
The prevalence of cirrhosis among relatives was calcu-
lated for all the exposed relatives and separately for parents,
siblings and offsprings. The number of exposed relatives
was adjusted according to the Strömgren’s method modi-
fied by Tillil [11] by age at diagnosis: the distribution of
patients according to the age at diagnosis of cirrhosis was
obtained from a cohort of 494 consecutive patients included
between 1981 and 1984 in a prospective study of the natural
history of cirrhosis [12] still in progress at our department.
Age groups were compared with the corresponding groups
in the Sicilian population in 1996 [13].
2.1.3. Genetic markers
The allele distribution of the two class III MHC genes,
C4 and BF, was investigated in all cirrhotic patients with
familiarity of cirrhosis (CASE families) and, as controls,
in an identical number of cirrhotic patients without famil-
iarity (CONTROL families), pair-matched for sex, age (±5
years) and etiology and in a cohort of 235 healthy blood
donors (BD) consecutively observed during the time of
the first study. No demographic differences were present
between the 93 pair-matched cirrhotic patients without
familiarity, used as controls, and the remaining 314 not
included in the analysis. No information was available on
whether the 235 healthy blood donors had a family history
of cirrhosis or not. Allomorphisms of C4 and BF were
studied by high-voltage agarose gel electrophoresis and
immunofixation [14]. The distribution of C4 null alleles
was obtained using the Hardy–Weinberg equilibrium. A
step-down multi-variable regression analysis by the logistic
model including 13 predefined variables was performed to
explore the role of C4 null alleles in familial clustering of
cirrhosis, independently from etiology, severity of the dis-
ease and demographic characteristics of index cases. The
selected variables were: sex, age, age at diagnosis, alcohol
abuse, HCV, HBsAg, Child-Pugh score, C4A3, C4AQ0,
C4B1, C4BQ0, BFS and BFF.
2.2. Second study: C4B allele deficiency and HCV
infection in familial cirrhosis
2.2.1. Family recruitment
Since the first study showed that C4B null allele is a pos-
sible risk indicator of cirrhosis mostly HCV related, we in-
vestigated the prevalence of this null allele (C4BQ0) and its
relationships with HCV infection in two sets of families in
which probands had HCV related liver cirrhosis. Only 20
families with at least one cirrhotic and one healthy sibling
(CASE families) were found in the first study; these fami-
lies and, as controls, 20 with at least two healthy siblings
(CONTROL families) and no other first degree relative with
cirrhosis were included in this second study. These control
families are the first 20 families who gave consent to be en-
rolled in the study.
2.2.2. Diagnostic work-up
To identify first degree relatives with cirrhosis all the par-
ticipants in the study underwent the following assessment:
physical examination particularly aimed at searching for
signs of liver disease (liver and spleen size and consistency,
spider naevi, palmar erythema, ascites, edema, abdomi-
nal wall collateral veins); blood testing for AST/ALT, anti
HCV and HBsAg. Anti HCV was determined by a second
generation enzyme–linked immunoabsorbent assay (ELISA
II- Ortho Diagnostic System, Raritan, NJ). HCV-RNA was
tested using reverse transcriptase-polymerase chain reaction
(RT-PCR) with primers based on the 5′ untranslated re-
gion (UTR) of the genome. Genotyping was performed by
RT-PCR with type specific primers according to Okamoto
[15]. HBsAg was detected using a commercially available
ELISA test (Abbott Diagnostic North Chicago); in HBsAg
positive relatives HBV-DNA was detected by quantitative
PCR (Amplicor HBV monitorTM test, Roche Diagnostic
System). All patients and relatives were also screened for
anti nuclear (ANA), anti mitochondria (AMA) and anti
smooth muscle autoantibodies (ASMA). Serum ceruloplas-
min was determined in subjects aged less than forty years.
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Table 1
Familiarity of cirrhosis in patients with cirrhosis and controls (n = 500)
No. of
patients
Median age
(range)
Male sex
(%)
Alcohol ≥80 g/die,
≥5 yrs (%)
Anti-HCV
+ ve alone (%)
HBsAg + ve
(%)
>1 Risk factor
(%)a
Patients with cirrhosis
CONTROL-families 407 57 (13–88) 212 (52.0) 56 (13.8) 313 (76.9) 27 (0.7) 51 (12.5)
CASE-families 93 58 (15–87) 51 (54.8) 9 (0.9) 76 (81.7) 6 (0.6) 11 (11.8)
Controlsb
CONTROL-families 487 54 (19–85) 285 (58.5) 4 (0.9) NTc NT NT
CASE-families 13 55 (16–8) 5 (38.5) 1 (7.7) NT NT NT
a Anti-HCV+ve and HBsAg+ve and/or alcohol ≥80 g/day for ≥5 years.
b Distribution percentage of chronic diseases among controls: absolute frequencies and (percentages): chronic pulmonary disease: 155 (31), inflammatory
bowel disease: 80 (16); cancer: 75 (15); chronic heart disease: 65 (13); metabolic-endocrine diseases: 30 (6); Others (mostly associated diseases): 95 (19).
c NT: not tested for anti HCV and HBsAg.
Relatives with physical signs of cirrhosis or with virus
hepatitis infection markers and/or hypertransaminasemia
were submitted for further laboratory tests (repeat AST/ALT,
bilirubin, alkaline phosphatase, prothrombin time, albumin,
gamma-globulins, full blood count) and abdominal ultra-
sound; when liver disease was suspected a liver biopsy was
suggested. Allomorphism of C4 genes was studied in all
cirrhotic patients to validate the results of the first study.
3. Results
3.1. First study: familiarity of cirrhosis
The principal characteristics of patients and controls are
reported in Table 1. Ninety-three (18.6%) of 500 patients
with cirrhosis had at least one first degree relative with
Table 2
Strömgren’s method of age correction for cirrhosis
1 2 3 4 5 6 7 8
No. Age group aN bN (×104) cN = aN/bN Relative risk dN (%) Cumulative relative risk eN =
∑
dN(%) Correction factor
1 0–9 2 7.03 0.28 0.15 0.15 0.00075
2 10–14 5 3.88 1.29 0.69 0.84 0.00495
3 15–19 6 4.34 1.38 0.74 1.58 0.0121
4 20–24 12 4.40 2.73 1.46 3.05 0.0231
5 25–29 10 4.40 2.27 1.22 4.26 0.0365
6 30–34 18 3.72 4.84 2.59 6.86 0.0556
7 35–39 38 3.36 11.31 6.07 12.92 0.0988
8 40–44 43 3.16 13.61 7.30 20.22 0.1656
9 45–49 77 2.58 29.84 16.01 36.23 0.2822
10 50–54 89 2.84 31.34 16.81 53.03 0.4463
11 55–59 74 2.74 27.01 14.48 67.52 0.6027
12 60–64 49 2.69 18.22 9.77 77.28 0.7240
13 65–69 28 2.43 11.52 6.18 83.46 0.8038
14 70–74 24 1.39 17.27 9.26 92.72 0.8812
15 75–79 14 1.42 9.86 5.29 98.01 0.9537
16 ≥80 5 1.35 3.70 1.99 100.00 0.9901
Total 494 517.2 186.47 100
Col. 3, aN, Number of patients with cirrhosis in the age at diagnosis class, given by D’Amico and co-workers [12]. Col. 4, bN, average age structure
of population of Sicily in 1996 [13]. Col. 6, dN(%) = cN × 100/
∑
cN. Col. 8, factor of age correction for relatives in respective age group = mean of
two consecutive cumulative relative risks from Col.7, divided by 100.
cirrhosis, as compared to 13 (2.6%) of 500 controls without
(OR 7.38; 95% CI 4.21–12.9). Sixteen of the 93 cirrhotic
patients with familiarity had more than one first degree rela-
tive with cirrhosis so that the total number of first degree rel-
atives with cirrhosis was 123. Three of the 13 controls with
first degree cirrhotic relatives had more than one cirrhotic
relative. No significant differences in HCV, HBsAg, alcohol
abuse, male gender and age were found between cirrhotic
patients with and without familiarity of cirrhosis (Table 1).
3.1.1. Disease risk in first degree relatives
Prevalence of cirrhosis among first degree relatives was
2.7% (123/4485) for cirrhotic patients and 0.4% (16/4086)
for controls, (OR 6.84; 95% CI 4.0–11.5). First degree cir-
rhotic relatives of cirrhotic patients were 81/1997 (4.0%)
siblings, 36/1000 (3.6%) parents, 6/1488 (0.4%) offspring.
First degree relatives with cirrhosis in controls were 8/500
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Table 3
Age-corrected empirical risk estimates of cirrhosis for first degree relatives of probands with cirrhosis and controls
Exposed relatives No. of first degree relatives with cirrhosis/No. of corrected exposed (observed number of subjects before correction)
In the families of cirrhotics In the families of controls Odds ratioa (95% CI)
Parents 36/806 (1000) 8/760 (1000) 4.8 (0.9 to 9.6 )
Siblings 81/1093 (1997) 7/931 (1789) 13.4 (1.7 to 25.0)
Offsprings 6/172 (1488) 1/191 (1297) 11.5 (20.8 to 43.9)
Total 123/2071 (4485) 16/1882 (4086) 8.0 (5.6 to 9.7)
a Using the corrected no. of exposed subjects after age correction.
fathers (1.6%) and 8/3586 remaining relatives (0.2%).
Sources of validation of the diagnosis of cirrhosis in the
secondary cases in the families of index cases and controls
were respectively the following: 57 and 7 were traced in
our files and were diagnosed according to the criteria used
for index cases; 33 and 4 were diagnosed in other hospitals,
as reported in medical records or discharge letters and in
34 and 5 the diagnosis was reported in the death certificate.
The age corrected risk estimates of cirrhosis for parents,
siblings, and offspring was calculated by correction factors
for each age class (Table 2), according to the Strömgren’s
method (Table 3). The age-corrected risk estimates of cir-
rhosis for first degree relatives of cirrhotic patients were:
81/1093 (7.4%) for siblings, 36/806 (4.5%) for parents and
6/172 (3.5%) for offspring; overall 123/2071 (5.9%). The
corresponding figures for the control group are reported in
Table 3: overall the age-adjusted prevalence of first degree
cirrhotic relatives was 0.8% (16/1882). The age-adjusted
OR for familiarity of cirrhotic patients versus controls was
8.0 (95% CI: 5.6–9.7).
3.1.2. Genetic markers in patients with cirrhosis
C4A and BF allele frequencies were found to be similar
in the 93 cirrhotic patients with familiarity, 93 cirrhotic pa-
tients without familiarity and 235 blood donors. However
the distribution of C4B alleles showed a significantly higher
prevalence of null alleles among CASE-families as com-
pared to CONTROL families and blood donors. According
to the Hardy–Weinberg equilibrium χ2, was 5.76; P = 0.016
(Table 4). A total of 33 out of 93 patients with familiarity
had C4B allele deficit (eight were homozygous) and were
Table 4
C4B phenotypes observed and predicted by the Hardy–Weinberg equilibrium in cirrhotic patients with (CASE-families) and without (CONTROL-families)
first degree relatives with cirrhosis and in blood donors
Patients with cirrhosis (n = 186) Blood donors (n = 235)
CASE-families = 93 CONTROL-families = 93
Observed n (%) Expected n (%) Observed n (%) Expected n (%) Observed n (%) Expected n (%)
Homozygous C4BQO 8 (8.6) 4 (4.8) 1 (1.1) 1 (1.1) 5 (2.1) 3 (1.3)
Heterozygous C4BQ0 25 (26.8) 33 (34.5) 14 (15.1) 15 (16.1) 39 (16.6) 43 (18.6)
No. C4BQ0 60 (64.6) 56 (60.7) 78 ( 83.8) 77 (82.8) 191 (81.3) 189 (80.1)
2 5.76 0.071 1.94
P-value 0.016 0.789 0.20
HCV positive versus 15 out of 93 patients without familiar-
ity (one was homozygous).
C4BQ0 allele distribution was also found to be the only
variable independently associated with familial clustering
of cirrhosis (OR 2.7; 95% CI = 1.83–3.96) in a step-down
multi-variable regression analysis by the logistic model, in-
cluding the 13 predefined variables reported in Section 2.
3.2. Second study: C4B allele deficiency and HCV
infection in familial cirrhosis
The number of first degree relatives in CASE families
was 148 (median 7, range 4–15) and 139 in CONTROL
families (median 6, range 4–14); 18 first degree relatives in
CASE-FAMILIES and 24 in CONTROL families did not
participate in the study: 23 of them were residing out of
Palermo, and 19 did not consent. A total of 130 subjects in
CASE-families (20 case patients and 110 relatives) and 115
in CONTROL-families (20 control patients and 95 relatives),
participated in this study.
There were 23 first degree relatives with cirrhosis in the
20 CASE families and obviously no case of cirrhosis in
the 20 CONTROL families. Therefore, there were 43 cir-
rhotic (29 Child–Pugh class A, 8 class B, and 6 class C)
subjects in CASE-families and 20 (14 Child-Pugh class A,
4 B, and 2 C) in CONTROL-families. Only one sister in
CONTROL-families, with normal AST/ALT, was found to
be HBsAg positive and HBV-DNA negative. In all cases,
normal levels of ceruloplasmin were found; autoantibodies
prevalence was similar in the two groups: 17.3% in case fam-
ilies (ANA 17.1%, ASMA 2.0%) versus 15.0% in control
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Table 5
C4BQ0 and HCV in patient with cirrhosis, first degree relatives without cirrhosis and whole families with (CASE-families) and without (CONTROL-families)
familial cirrhosis
HCV+ P-value∗ C4BQ0 (homozygous) P-value∗ HCV+ and C4BQ0 P-value∗
Patients with cirrhosis
CASE-families 20 + 23 43 ns 16 (3) 0.01 16 0.0001
CONTROL-families 20 20 2 (0) 1
Relatives without cirrhosis
CASE-families 87 16 0.001 22 (4) 0.01 0 ns
CONTROL-families 95 2 11 (0) 1
Whole families
CASE-families 130 59 0.0001 38 (7) 0.01 16 0.001
CONTROL-families 115 22 13 (0) 2
∗ 2 test: only P values ≤ 0.0125 were considered as statistically significant according to Bonferroni’s adjustment for multiplicity of tests [16].
families (ANA 15.0%, ASMA 0%), P value not significant.
No AMA positive subjects were found in either group.
C4BQ0 and HCV distribution in the two sets of families
are reported in Table 5.
3.3. C4BQ0 allele prevalence and familial spreading of
HCV
Null C4B alleles were significantly more frequent in
CASE than in CONTROL family subjects (38/130 ver-
sus 13/115, P = 0.001). Overall 59/130 subjects in case
families were anti-HCV positive (49 HCV-RNA posi-
tive) as compared to 22/115 in CONTROL families (19
HCV-RNA positive): P-value for anti-HCV = 0.00001 and
for HCV-RNA = 0.0002. All the cirrhotic subjects either
in CASE (n = 43) or in CONTROL families (n = 20) were
anti-HCV positive. Among non-cirrhotic subjects anti-HCV
positive were 16/87 (13 HCV-RNA positive) in CASE and
2/95 (1 HCV-RNA positive) in CONTROL families: the
P-value for anti-HCV = 0.0002 and for HCV-RNA =
0.0004.
Genotyping was performed for all 68 HCV-RNA positive
subjects: 1b was the only genotype found.
A total of 16/130 (12.3%) subjects in CASE families were
anti-HCV positive and had null alleles for C4B as compared
to 2/115 (1.7%) in CONTROL families (P = 0.0009) and
18/19 subjects with the association of C4BQ0 and anti HCV
positivity had cirrhosis; this association was found in only
one healthy first degree relative.
Therefore the CASE families had a higher prevalence of
C4 null alleles and HCV positivity: both markers were as-
sociated almost exclusively in patients with cirrhosis.
4. Discussion
The aim of the present two studies was to investigate the
familial clustering of cirrhosis and the role of C4 alleles and
HCV as risk factors for this aggregation.
In the first study we found that 18.6% of patients with
cirrhosis have at least one first degree relative with cirrhosis,
confirming the results of three previous studies from Italy
[1,17,18]. However the most important finding of this study
was that the age adjusted risk of cirrhosis among the first
degree relatives of cirrhotic patients was 5.9% as compared
to 0.8% for first degree relatives of controls, corresponding
to an odds ratio of 8.0 (CI 5.6 – 9.7). This information was
previously unknown and suggests that it would be important
to aim at the prevention or at least at the early diagnosis of
cirrhosis in the families of cirrhotic patients.
The significantly higher prevalence of C4BQ0 among
index cases with familiarity of cirrhosis mostly HCV re-
lated, suggests a possible role of this MHC class III antigen
as genetic marker of familial aggregation of cirrhosis and
leads to the hypothesis of a genetic predisposition to liver
cirrhosis.
Many studies on familial spreading of HCV are avail-
able from the literature. In a cumulative analysis of Ital-
ian studies recently published [19–22] the HCV pooled
prevalence among 1796 first degree relatives was 2.7%
(range 1.7–3.8%). More recently in a systematic review
including 11 controlled studies [23], the pooled preva-
lence of anti-HCV positivity was 4.0% among adult sib-
lings and no-sexual contacts of patients with HCV-related
chronic liver disease, as compared with none in negative
controls.
The second study explored this hypothesis in families of
patients with HCV related cirrhosis. As expected anti-HCV
and HCV-RNA prevalence were significantly higher in fam-
ilies with at least one first degree relative with cirrhosis than
in those without, suggesting a somewhat facilitated spread-
ing of the virus infection in the families with more cirrhotic
subjects. This suggestion is also supported by the higher
prevalence of C4BQ0 found in families with higher preva-
lence of the disease. It is of special interest in this regard the
finding that in the studied families of cirrhotic probands, all
but one of the subjects infected with HCV and expressing
C4BQ0 were cirrhotic, whereas nearly half of the subjects
who were HCV infected and not expressing C4BQ0 were
not.
Our finding that HCV infection is associated with the
development of cirrhosis in C4BQ0 subjects, supports the
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hypothesis of a genetically transmitted impairment of HCV
clearance in families with familial cirrhosis.
Lack of C4B could limit the capacity to weed out exoge-
nous and endogenous pathogenic factors and may contribute
to explain the association with some infective and immune
diseases. It is of interest in this respect that C4BQ0 has an
important role in HIV disease: HIV infected patients have
a remarkably high prevalence of C4B null alleles [24] and
the asymptomatic period is significantly shorter in patients
with C4B null alleles [25].
Moreover an association of autoimmune hepatitis and pri-
mary biliary cirrhosis with C4AQ0 has been recently demon-
strated [10]. There is evidence for a possible role of MHC
II genes in the outcome of HCV infection [3,7–9] and sev-
eral studies show a relationship among certain I-II MHC
alleles and the enhanced risk of the progression of HCV
infection towards cirrhosis [4–6]. Only one of the studies
so far published has analyzed the role of III MHC alle-
les in HCV clearance, without achieving conclusive results
[7].
An additional hypothesis is that C4 alleles have a role
in regulating liver inflammation and fibrogenesis: in fact,
C4AQ0 has been found to be associated with type 1 and
2 autoimmune hepatitis and primary biliary cirrhosis [10],
and our results suggest that C4B deficiency may act as a
factor facilitating fibrogenesis independently on the mecha-
nism of impaired HCV clearance. These data further support
the hypothesis that chronic liver diseases result from an in-
terplay of environmental factors and genes, each contribut-
ing to the susceptibility and the clinical heterogeneity of the
disease.
In conclusion there is a considerable risk of familial ag-
gregation of cirrhosis. In HCV related disease, this risk is
associated with C4BQ0 alleles. The observation that C4BQ0
alleles are significantly associated with familial clustering
of liver cirrhosis is novel and suggests class III MHC al-
leles as markers for genetic predisposition to chronic liver
disease.
Conflict of interest statement
None declared.
Acknowledgements
This paper is dedicated to the memory of Melchiorre Brai,
Professor in Immunology, University of Palermo.
References
[1] Pagliaro L, Saracci R, Bardelli D, Filippazzo G. Chronic liver disease.
Ital J Gastroenterol 1986;14:90–5.
[2] Pasta L, D’Amico G, Vizzini G, Caltagirone M, Pagliaro L. Famil-
iarity of cirrhosis. Familial predisposition or environmental factors?
J Hepatol 1989;9:S203.
[3] Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, et al. Genes
of the major histocompatibility complex class II influence the out-
come of hepatitis C virus infection. Gastroenterology 1997;113:1675–
81.
[4] Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, et
al. Association between HLA class II alleles and protection from or
susceptibility to chronic hepatitis, C. J Hepatol 1998;28:1–7.
[5] Hohler T, Gerken G, Notghi A, Knolle P, Lubjunh R, Taheri H, et
al. MHC class II genes influence the susceptibility to chronic active
hepatitis, C. J Hepatol 1997;27:259–64.
[6] Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani
S, et al. Influence of HLA haplotypes on the clinical courses of
individuals infected with hepatitis C virus. Hepatology 1998;27:240–
4.
[7] Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01
allele with spontaneous viral clearance in an Irish cohort infected
with hepatitis C virus via contaminated anti-D immunoglobulin. J
Hepatol 1999;30:979–83.
[8] Thursz M, Yallop R, Goldin R, Trepo C. Thomas HC for the HEN-
CORE group. Influence of MHC class II genotype on outcome of
infection with hepatitis C virus. Lancet 1999;354:2119–24.
[9] Manns MP, Kruger M. Immunogenetics of chronic liver diseases.
Gastroenterology 1994;106:1676–97.
[10] Asti M, Martinetti M, Zavaglia C, Cuccia MC, Gusberti L, Tinelli
C, et al. Human leukocyte antigen class II and III alleles and sever-
ity of hepatitis C virus-related chronic liver disease. Hepatology
1999;29:1272–9.
[11] Tillil H, Köbberling J. Age corrected empirical genetic risk estimates
for first degree relatives of IDDM patients. Diabetes 1987;36:93–9.
[12] Pagliaro L, Pasta L, D’Amico G, Puleo A, Politi F, Vizzini G, Natural
history of cirrhosis: Predictors of death risk overview of published
studies and validation in a new test. In: Dobrilla G, Felder M, De
Pretis G (Eds.), Advances in hepatobiliary and pancreatic diseases:
Special Clinical Topics, 1994. p. 82–93.
[13] Distribuzione della popolazione Siciliana. In: Bollettino
dell’Osservatorio Epidemiologico Regionale dell’Assessorato San-
ità della Regione Sicilia. Publisicula ed. Palermo 1 (1998) 19–
20.
[14] Srivistava N, Srivistava LM. Association between C3 comple-
ment types and childhood cirrhosis. Hum Hered 1985;36:268–
71.
[15] Okamoto H, Tokita M, Sakamoto M, Horikita M, Iizuka H, Mishiro
S. Characterization of the genomic sequence of type V (or 3a)
hepatitis C virus isolates and PCR primers for specific detection. J
Gen Virol 1993;74:2385–90.
[16] Armitage P, Comparison of different groups. In: Statistical Meth-
ods in Clinical Research. Blackwell Scientific Publication, 1971.
p. 188–214.
[17] Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Mar-
tin C, et al. Dionysos Group. Prevalence of chronic liver disease
in the General population of Northern Italy: The Dionysos study.
Hepatology 1994;6:1442–9.
[18] De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic
factors in cirrhosis with and without hepatocellular carcinoma: a
multicenter Italian study. Hepatology 1994;20:1225–30.
[19] Sagnelli E, Gaeta GB, Felaco FM, Stroffolini T, Conti S, Gliemo
A, et al. Hepatitis C virus infection in households of anti-HCV
chronic carriers in Italy: a multicentre case-control study. Infection
1997;25:346–9.
[20] Demelia L, Vallebona E, Poma R, Sanna G, Masia G, Coppola RC.
HCV transmission in family members of subjects with HCV related
chronic liver disease. Eur J Epidemiol 1996;12:45–50.
[21] Caporaso N, Ascione A, D’Antonio M, Di Costanzo GG, Galeota
Lanza A, Tremolada F, et al. Prevalence of anti HCV among spouses
and offspring of anti-HCV positive subjects: an Italian multicentre
study. Ital J Gastroenterol 1995;27:5–7.
L. Pasta et al. / Digestive and Liver Disease 36 (2004) 471–477 477
[22] Coltorti M, Caporaso N, Morisco F, Suozzo R, Romano M,
D’Antonio M. Prevalence of hepatitis C virus infection in the house-
hold contacts of patients with HCV-related chronic liver disease.
Infection 1994;22:183–6.
[23] Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of
hepatitis C virus: a systematic review. J of Viral Hepatitis 2000;7:93–
103.
A Masterclass in Inflammatory Bowel Disease 
will be held in Oxford on Wednesday 1st September 2004 
This Masterclass has been designed for Consultants and Registrars, including those 
who do not specialise in gastroenterology.  Topics will include: - 
Pathogenesis 
Surgical Treatment 
Diagnosis 
Problems in Medical Management 
Course fee:   £100 
Board and accommodation is available at Wadham College at extra cost. 
Six bursaries will be available for applicants training in gastroenterology or in 
research posts in British Hospitals. 
For further details and application forms contact:- 
Professor Derek P. Jewell 
Radcliffe Infirmary 
Woodstock Road 
OXFORD OX2 6HE 
United Kingdom 
Tel: + 44 1865 224829 
Fax: + 44 1865 790792 
E-mail: derek.jewell@ndm.ox.ac.uk
http://www.medicine.ox.ac.uk/gastro
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